Comparing the adjuvant chemotherapy regimens for advanced gastric cancer after laparoscopic D2 radical gastrectomy

Comparison of adjuvant chemotherapy regimens for advanced gastric cancer after laparoscopic D2 radical gastrectomy

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR-IPR-15007047

Enrollment

Unknown

Registered

2015-09-09

Start date

2016-01-01

Completion date

Unknown

Last updated

2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

gastric cancer

Interventions

CAPOX:Oxaliplatin 130mg/m2, iv drip d1

Capecitabine 1000mg/m2, Po, bid, d1-14, 21d/cycle, total of 8 cycles

SOX:Oxaliplatin 130mg/m2, iv drip d1

S1 60mg, Po, bid, d1-14, 21d/cycle, total of 8 cycles.

Eligibility

Sex/Gender

All

Age

20 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. Histologically proven adenocarcinoma of the stomach; 2. Clinical stage IB-III; 3. No bulky lymph node metastasis is detected by abdominal CT; 4. Age ranging between 20 80 years; 5. No previous treatment with chemotherapy or radiation therapy for any tumors; 6. No previous surgery for the present disease; 7. No obvious contraindications for laparoscopic operation; 8. R0 removal can be achieved by laparoscopy.

Exclusion criteria

Exclusion criteria: 1. Past history ofper abdominal surgery; 2. Past history of surgery for the gastrointestinal tract; 3. Body mass index exceeding 30 kg/m2.

Design outcomes

Primary

Measure	Time frame
3 year overall survival;3 year progression free survival;	—

Secondary

Measure	Time frame
quality of life;	—

Countries

China

Contacts

Public ContactJian Liu

zyypw15a@163.com+86 13821221879

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026